Sanofi

What they do

Sanofi operates as a pharmaceutical company with segments including Specialty Care, Vaccines, General Medicines, and Consumer Healthcare. Its key products include Dupixent, vaccines, and treatments for rare diseases, oncology, and immunology. The company sells in over 100 countries and conducts R&D across multiple therapeutic areas.

Revenue drivers

• Dupixent (dupilumab) — Partnered with Regeneron, Dupixent is a major revenue driver for Sanofi in immunology and allergy indications, contributing significantly to specialty care sales.
• Vaccines — Vaccines for influenza, polio, and other diseases are a core product line, with a global manufacturing and distribution network.
• Rare Disease and Oncology — Treatments for rare diseases (e.g., enzyme replacement therapies) and oncology products, including those from the prior partnerships, add to the specialty portfolio.
• General Medicines and Consumer Health — Includes established brands and over-the-counter products, providing a diversified revenue base alongside specialty and vaccines.

Recent performance

Sanofi reported FY2025 results in its 20-F filed February 2026. Revenue grew, driven by Dupixent and vaccines, with notable sales in the U.S. and other regions. Operating income and net income were affected by R&D spending and restructuring costs. The company highlighted strong growth in its core assets, including Dupixent and newer launches, while managing the impact of patent expiries and competition.

Strategy

Sanofi's strategy centers on advancing its specialty care pipeline, particularly in immunology, oncology, and rare diseases. The company is investing in R&D for next-generation therapies, including biologics and mRNA-based vaccines. It aims to drive growth through key brands like Dupixent and expand its presence in high-potential markets. Sanofi also focuses on operational efficiency and portfolio optimization, including divesting non-core assets like its consumer health business.

Risks

• Patent expiries and biosimilar competition — Key products face patent cliffs, exposing revenue to biosimilar erosion.
• Regulatory and pricing pressures — Government price negotiations and healthcare reforms in major markets could reduce drug prices.
• R&D and pipeline execution — Clinical trial failures or regulatory setbacks for pipeline candidates could hurt future growth.
• Supply chain and manufacturing — Disruptions in vaccine production or quality issues could impact product availability and sales.

Outlook

Management expects continued sales growth driven by Dupixent, vaccines, and new product launches. The company anticipates margin improvement from cost discipline and portfolio optimization. Sanofi plans to invest in R&D for key therapeutic areas and execute strategic partnerships. The outlook includes potential impacts from competition, regulation, and macroeconomic conditions.